Bottom line. COR’s F3Q26 (calendar 2Q26) beat was driven by segment profit rather than revenue. Adjusted EPS of $4.48 beat pre-print consensus by $0.13, or 3.0%, while total segment operating income of $1.2B came in about 4.0% above consensus. Revenue beat by only 0.5%. The operating margin led beat is a positive signal at this stage, but the midpoint of FY26 adjusted EPS guidance rose by just $0.05, and the result included acquisition mix, manufacturer-price timing, held-for-sale accounting and repurchase support. The quarter strengthens confidence in FY26 delivery, but it does not establish a higher normalized FY27 earnings path.
Profit conversion carried the beat
Revenue of $84.8B was about $445M above consensus. Adjusted gross margin of 4.16% beat by 30 bps, total segment operating income rose 17.0% to $1.2B and adjusted operating margin expanded 15 bps to 1.46%. The operating-income surprise slightly exceeded the adjusted EPS beat, while adjusted net income grew 11.2% and adjusted EPS grew 12.0%. The profit-led surprise is more supportive of the operating case than the modest revenue beat alone. But the 61 bps year-over-year gross-margin increase was largely due to the February OneOncology acquisition, so the increase partly reflected mix rather than underlying margin expansion.
Sources: Cencora F3Q26 earnings release; StreetAccount.
U.S. Healthcare Solutions provided the clearest evidence of underlying profit strength. Revenue of $74.9B missed consensus by 0.4%, but segment operating income rose 15.9% to $966M, 2.8% above consensus, and margin increased 12 bps to 1.29%. GLP-1 sales added $2.3B of year-over-year revenue, while manufacturer list-price reductions created a $2.4B headwind to revenue growth. The prior-year loss of an oncology customer and lower sales to a large mail-order customer also weighed on revenue. Against that backdrop, specialty growth was strong across the MSOs, health systems and physician practices, while the core U.S. business delivered double-digit organic operating-income growth excluding OneOncology and the lost customer. The revenue miss matters less than the segment’s profit resilience through price and customer noise.
OneOncology outperformed, but the 12-month EPS outlook remains neutral
OneOncology and Retina Consultants of America both performed ahead of management’s expectations, and OneOncology operating income was modestly better than initially expected. That supports the strategic rationale for adding physician-practice platforms around Cencora’s specialty distribution and GPO capabilities. It does not yet prove per-share accretion. On a 12-month basis, management still expects OneOncology to be neutral to adjusted EPS net of financing. F3Q26 net interest expense increased $59M year-over-year, primarily because of acquisition financing. Integration is progressing, but management said cross-platform clinical-trial capability sharing remains early, while new analytics and service offerings are future-stage opportunities.
International broadened the beat, although one timing benefit will not repeat in F4Q26. Segment operating income rose 20.8%, or 23.1% in constant currency, to $166M and beat consensus by 1.8%. World Courier and European 3PL each delivered double-digit profit growth, but European distribution again benefited from the timing of manufacturer price adjustments in a developing market, which management does not expect in F4Q26. Other operating income rose 24.8% to $109M and beat by 10.6%, but management said the majority of the growth came from held-for-sale accounting, which reduced depreciation expense; underlying MWI growth was about 10%. Every segment beat, but the U.S. result carries the strongest evidence of repeatability, International needs a timing adjustment, and Other was the lowest-quality contributor.
Sources: Cencora F3Q26 earnings release and call; Graver Research analysis.
Segment profit supported the adjusted EPS beat
GAAP EPS of $3.94 was $0.54 below adjusted EPS, but the net gap contained large offsetting items. The reconciliation added back $0.60 for deal and integration expenses, $0.32 for intangibles amortization and $0.18 for restructuring; LIFO and litigation/opioid credits reduced the bridge by $0.31 and $0.35, respectively. The adjusted result was still supported by the segment-profit beat, rather than created by exclusions. Capital allocation also helped: Cencora repurchased $1.0B of stock at an average $268 per share, and diluted shares fell 0.7% to 193.9M. Buybacks are part of the company’s earnings algorithm, but their contribution does not prove organic growth or OneOncology accretion.
Source: Cencora fiscal Q3 2026 earnings release, GAAP-to-adjusted reconciliation.
The raise de-risked FY26 without lifting the implied F4Q26 EPS path
On August 4, FY26 adjusted EPS consensus was $17.78 and F3Q26 consensus was $4.35. With $8.83 of adjusted EPS already earned in the first half, the pre-print path implied $4.60 for F4Q26. The new $17.85 guidance midpoint, less nine-month adjusted EPS of $13.31, implies $4.54 for F4Q26. In other words, the $0.05 midpoint raise captured less than half of the $0.13 F3Q26 beat, leaving the midpoint-implied F4Q26 EPS path about $0.06 below the pre-print path. The guide raised the FY26 floor, but it did not establish a higher exit rate. A lower share-count assumption also supported EPS, while net-interest guidance increased by $5M to approximately $490M following the repurchases.
F4Q26 still requires a strong operating and cash finish. Cencora raised consolidated adjusted operating-income growth guidance to 13%–14% from 12%–14%, narrowed U.S. growth to 14.5%–15.5%, and lifted International and Other to approximately 9% and 10%.Using the midpoint or point guidance and the recast FY25 bases, Graver Research calculates that F4Q26 total segment operating income would need to grow about 20.1% year-over-year. Management expects F4Q26 to deliver the strongest U.S. organic growth of FY26, excluding OneOncology, at the guidance midpoint, as the lost oncology customer is fully lapped and expenses become easier. Adjusted free cash flow adds another back-end test: $1.1B through nine months against an unchanged approximately $3.0B target leaves about $1.9B, or 62% of the annual goal, for F4Q26. Cencora’s cash flow is seasonally weighted to its fiscal fourth quarter, but the F4Q26 conversion still has to occur.
Sources: Cencora fiscal Q2 and Q3 2026 earnings materials; Koyfin consensus; FY2025 segment recast; Graver Research analysis.
FY26 estimates rose; FY27 did not
COR rose 3.6% on August 5 and was 3.8% above the August 4 close through August 21, versus a 0.8% decline for the S&P 500 and a 7.7% gain for XLV. FY26 EPS consensus increased $0.09 to $17.87 over that period, while FY27 consensus slipped $0.03 to $19.79. The stock is currently trading near 17.0x NTM EPS, modestly above its 10-year plus-one-standard-deviation level and nearly 2 turns above the 13.8x median. That premium leaves less room for an incomplete FY27 bridge. Assuming a midyear close, management’s MWI-Covetrus modeling implies a $150M FY27 operating-income headwind in Other and an approximately $0.35 EPS headwind; management advised investors not to include EyeSouth in models because its timing remains uncertain. The November guide has to show whether core growth, OneOncology and capital deployment can offset the modeled MWI headwind.
The next test is the FY27 bridge
F3Q26 showed that Cencora’s specialty platform and core distribution economics can deliver through price and customer noise. It also reduced OneOncology execution risk and made FY26 more achievable. What remains unresolved is whether OneOncology becomes accretive net of financing, whether International and Other can grow after the timing and accounting benefits normalize, and whether F4Q26 converts earnings into the cash embedded in guidance. The F4Q26 result and November FY27 outlook are therefore the next tests. U.S. organic acceleration, logistics growth without another price-timing benefit, full-year cash conversion and an FY27 guide that absorbs the MWI headwind without relying on outsized repurchases would strengthen the case that F3Q26 momentum can carry into FY27. Another timing-supported beat, weak cash conversion or a lower FY27 earnings base would leave the normalized FY27 case unresolved. For now, the FY26 case improved more than the normalized FY27 case.